This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Updated Feb. 8, 2022 4:16 pm ET / Original Feb. 8, 2022 4:15 pm ET
- Order Reprints
- Print Article
Pfizer shares dropped sharply on Tuesday after the company’s 2022 sales guidance appeared to fall short of expectations.
The guidance that Pfizer (ticker: PFE) presented, however, doesn’t take into account future sales of Pfizer’s Covid-19 vaccine and antiviral, but only sales already made. The number will likely climb upward as the year progresses, suggesting that the selloff on Tuesday may have been based on a misunderstanding.